|
Paul Schwedelson reported this week in the Philadelphia Business Journal that, “after failing to find a buyer at sheriff’s sale, the former Navy Yard home of pharmaceutical giant GSK has finally been sold.” The Eastern Atlantic States Regional Council of Carpenters purchased the vacant 207,779-square-foot building at 5 Crescent Drive for $52 million, 60% less than it last traded for eight years ago, he reported, and will move around 125 employees there from its current Philly headquarters within the next six months. The union will also construct a training facility in the parking lot of the former GSK property (archive photo from 2016 above), which has been closed since 2022 when the pharma giant downsized and moved to offices at FMC Tower in University City.
“This is about building for the future,” William Sproule, the union’s executive secretary-treasurer, said in a statement to Schwedelson, expressing a sentiment once held by GSK leaders. GSK’s campus at Navy Yard was first occupied in 2012 when Site Selection noted other biopharma investment in the neighborhood from such companies as Iroko Pharmaceuticals (which went out of business in 2020.) The modern GSK facility also was a primary discussion point with the global head of design and change management for GSK’s Worldwide Real Estate & Facilities team in this 2016 Site Selection Investment Profile.
As noted in another Site Selection Investment Profile last year, 2025 marked 25 years since PIDC, the public-private economic development partner of the City of Philadelphia, acquired the 1,200 Navy Yard property from the federal government. And the life sciences remain key to Navy Yard and to the region. Today, says PIDC, the Navy Yard is “an expanding community of 16,500 employees and 150 employers” occupying 8 million sq. ft. of space, but the property can still support an additional 8.9 million sq. ft. of commercial and residential development at full buildout. In addition to Urban Outfitters’ headquarters and various manufacturers and corporate R&D locations, the Navy Yard still has a mix of life sciences firms that includes Adaptimmune, Iovance Biotherapeutics, Minaris Advanced Therapies and Orchestra Life Sciences, which announced in November it was moving its global HQ to Philly from Montreal.
Minaris operations incorporate a major site formerly operated by China-based WuXi Advanced Therapies, which in December 2024 sold its U.S. and UK operations to health care private equity firm Altaris after new U.S. legislation came forward potentially restricting partnerships with certain Chinese companies. However, WuXi AppTec still moved forward in early 2025 with a $510 million manufacturing campus in Middletown, Delaware, that aims to be phase-one operational by the end of this year. — Adam Bruns
|